Please assess the completion status of the following clinical trial:

Trial Title: A Study of Nasal Glucagon in Participants With Type 1 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of Type 1 Diabetes Mellitus (T1DM) for at least 2 years and receiving daily insulin since the time of diagnosis~Exclusion Criteria:~* Have a history of hypersensitivity to glucagon or any related products or severe hypersensitivity reactions (such as angioedema) to any drugs~* Have a history of pheochromocytoma (that is, adrenal gland tumor) or insulinoma~* Occurrence of an episode of severe hypoglycemia (defined as requiring the assistance of another person in the 1 month prior to enrolling in the study)~* Have a history of epilepsy or seizure disorder~* Are women who are pregnant or lactating~* Have, except for the current regimen of insulin therapy and concomitant medication, regular use of or intended use of any over-the-counter or prescription medications or nutritional supplements that treat hyperglycemia or insulin resistance or that promote weight loss within 14 days before dosing~* Daily use of systemic beta-blocker, indomethacin, warfarin or anticholinergic drugs~* Require daily insulin treatment greater than (\>)1.5 unit/kilograms (U/kg)/body weight

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- Nasal Glucagon (Type: EXPERIMENTAL): Single dose of Nasal Glucagon.
- Intramuscular Glucagon (Type: ACTIVE_COMPARATOR): Single intramuscular (IM) dose of Glucagon.

Based on this trial design, predict the completion outcome and termination type (if applicable).